Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of Gemcitabine and Docetaxel in Combination With Hydroxychloroquine (Autophagy Inhibitor) in Patients With Recurrent Osteosarcoma

NCT03598595 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT03598595
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03598595 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of Gemcitabine and Docetaxel in Combination With Hydroxychloroquine (Autophagy Inhibitor) in Patients With Recurrent Osteosarcoma
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
January 28, 2019
Completion date
May 31, 2027
Enrollment
31 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent osteosarcoma, refractory osteosarcoma